Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
England’s health care costs watchdog the National Institute for Health and Care Excellence (NICE) has issued further draftguidance which recommends Jardiance (empagliflozin), marketed by German family-owned pharma major Boehringer Ingelheim, for treating type 2 diabetes.
In a preliminary appraisal last summer (The Pharma Letter August 28, 2014), the NICE called for the company to provide more evidence to demonstrate that empagliflozin is a good use of NHS resources when compared with other treatments that are already available. Boehringer Ingelheim responded and submitted a new cost-effectiveness model which showed that empagliflozin combination therapy is a cost effective treatment option for some people with type 2 diabetes.
http://www.thepharmaletter.com/arti...d-boehringer-s-type-2-diabetes-drug-jardiance
In a preliminary appraisal last summer (The Pharma Letter August 28, 2014), the NICE called for the company to provide more evidence to demonstrate that empagliflozin is a good use of NHS resources when compared with other treatments that are already available. Boehringer Ingelheim responded and submitted a new cost-effectiveness model which showed that empagliflozin combination therapy is a cost effective treatment option for some people with type 2 diabetes.
http://www.thepharmaletter.com/arti...d-boehringer-s-type-2-diabetes-drug-jardiance